

From: [Director Discretionary Decision](#)
To: [Argall, Arthur](#)
Cc: [Eylea](#); [GRP-PW-EYLEA-Biosimilars@paulweiss.com](#); [Lora Green](#); [Aviv Zalcenstein](#); [Mike Cottler](#); [Michael Johnson](#); [Keith Zullo](#); [Franklin Chu](#); [Robert Cerwinski](#)
Subject: RE: IPR2025-00456--Patent Owner's request to file a reply to Petitioner's Discretionary Denial Opposition
Date: Thursday, May 22, 2025 1:38:24 PM

Counsel –

Patent Owner is authorized to file a 5-page reply to Petitioner's Opposition to Patent Owner's request for discretionary denial, limited to addressing Petitioner's *Sotera* stipulation, due no later than May 27, 2025. Petitioner is authorized to file a 5-page sur-reply, limited to addressing issues raised in Patent Owner's reply, due no later than May 30, 2025.

From: Argall, Arthur <aargall@wc.com>
Sent: Wednesday, May 21, 2025 4:10 PM
To: Director_Discretionary_Decision <Director_Discretionary_Decision@uspto.gov>
Cc: Eylea <Eylea@wc.com>; GRP-PW-EYLEA-Biosimilars@paulweiss.com; Lora Green <lgreen@geminilaw.com>; Aviv Zalcenstein <azalcenstein@geminilaw.com>; Mike Cottler <mcottler@geminilaw.com>; Michael Johnson <mjohnson@geminilaw.com>; Keith Zullo <kzullo@geminilaw.com>; Franklin Chu <fchu@geminilaw.com>; Robert Cerwinski <rcerwinski@geminilaw.com>
Subject: IPR2025-00456--Patent Owner's request to file a reply to Petitioner's Discretionary Denial Opposition

CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before responding, clicking on links, or opening attachments.

Dear Honorable Director,

Patent Owner Regeneron is seeking authorization to file a 5-page reply to Petitioner Celltrion's Opposition to Regeneron's Discretionary Denial Brief to address Celltrion's *Sotera* stipulation filed with its Opposition in connection with the question whether discretionary denial is warranted under *Fintiv*, to be filed no later than May 27. Petitioner Celltrion does not oppose but asks that if authorization to file the reply is granted, that it be granted leave to file a 5-page sur-reply due one week later on June 3. Regeneron does not oppose Celltrion's request for a sur-reply if Regeneron is granted a reply.

Best,

Arthur J. Argall
Associate | Williams & Connolly LLP

680 Maine Avenue, S.W., Washington, DC 20024
(P) 202-434-5251 | (202) 434-5029
aargall@wc.com | www.wc.com

This message and any attachments are intended only for the addressee and may contain information that is privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank you.